Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

European Journal of Endocrinology

Volumn 159, Issue 5, 2008, Pages 517-523

  Jimenez, Camilo ^a   Burman, Pia ^b   Abs, Roger ^c   Clemmons, David R ^d   Drake, William M ^e   Hutson, Kent R ^f   Messig, Michael ^g   Thorner, Michael O ^h   Trainer, Peter J ⁱ   Gagel, Robert F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^g PFIZER INC   (United States)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PLACEBO; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; IMAGE ANALYSIS; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; SIDE EFFECT; SURGICAL TECHNIQUE; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND;

EID: 56749158820     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0205     Document Type: Article

References (42)

1. Scacchi M & Cavagnini F. Acromegaly. Pituitary 2006 9 297-303.
2. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102.
3. Freda PU, Wardlaw SL & Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery 1998 89 353-358.
4. Holdaway IM & Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999 2 29-41.
5. Melmed S. Acromegaly and cancer: not a problem? Journal of Clinical Endocrinology and Metabolism 2001 86 2929-2934.
6. Prabhu SS, Aldape KD, Gagel RF, Benjamin RS, Trent JC & McCutcheon IE. Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma. Canadian Journal of Neurological Sciences 2003 30 378-383.
7. Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Reviews in Endocrine and Metabolic Disorders 2008 9 67-70.
8. Nomikos P, Buchfelder M & Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 2005 152 379-387.
9. Ludecke DK & Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 2006 83 230-239.
10. Eastman RC, Gorden P, Glatstein E & Roth J. Radiation therapy of acromegaly. Endocrinology and Metabolism Clinics of North America 1992 21 693-712.
11. Biermasz NR, Dulken HV & Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical Endocrinology 2000 53 321-327.
12. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573.
13. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ & Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. American Journal of Medicine 1986 81 457-462.
14. Littley MD, Shalet SM, Beardwell CG, Robinson EL & Sutton ML. Radiation-induced hypopituitarism is dose-dependent. Clinical Endocrinology 1989 31 363-373.
15. Millar JL, Spry NA, Lamb DS & Delahunt J. Blindness in patients after external beam irradiation for pituitary adenomas: two cases occurring after small daily fractional doses. Clinical Oncology 1991 3 291-294.
16. Meyers CA, Geara F, Wong PF & Morrison WH. Neurocognitive effects of therapeutic irradiation for base of skull tumors. International Journal of Radiation Oncology, Biology, Physics 2000 46 51-55.
17. Racine MS & Barkan AL. Medical management of growth hormone-secreting pituitary adenomas. Pituitary 2002 5 67-76.
18. Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A & Trainer PJ. Current status and future opportunities for controlling acromegaly. Pituitary 2002 5 185-196.
19. Freda PU. Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018.
20. Freda PU. How effective are current therapies for acromegaly? Growth Hormone and IGF Research 2003 13 (Suppl A) S144-S151.
21. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P. Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.
22. Ben-Shlomo A & Melmed S. Somatostatin agonists for treatment of acromegaly. Molecular and Cellular Endocrinology 2008 286 192-198.
23. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
24. Besser GM, Burman P & Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187-193.
25. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA & Lamberts SW Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism 2001 86 478-481.
26. Colao A, Pivonello R, Aurienima RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
27. Frohman LA & Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 2007 10 283-289.
28. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
29. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Sailer B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82.
30. Lundin P & Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528.
31. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC & Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 205-216.
33. Colao A, Cerbone G, Cappabianca P, Ferone D, Alfieri A, Di Salle F, Faggiano A, Merola B, de Divitiis E & Lombardi G. Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. Journal of Endocrinological Investigation 1998 21 284-290.
34. Greenman Y, Ouaknine G, Veshchev I, Reider G II, Segev Y & Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical Endocrinology 2003 58 763-769.
35. Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y & Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. Journal of Neurosurgery 2003 98 359-365.
36. Klijn JG, Lamberts SW, de Jong FH, van Dongen KJ & Birkenhager JC. Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinologica 1980 95 289-297.
37. Donangelo I & Melmed S. Implication of pituitary tropic status on tumor development. Frontiers of Hormone Research 2006 35 1-8.
38. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
39. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473.
40. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
41. Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN & Stewart PM. Radiotherapy for non-function pituitary tumours. Clinical Endocrinology 1998 48 331-337.
42. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G & Enrici RM. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clinical Endocrinology 2005 62 210-216.